OneMedNet flags going-concern doubt with $137K cash
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
OneMedNet Corp (ONMD) reported third-quarter 2026 revenue of $1.023 million, versus $177,000 a year earlier, while net loss widened to $2.660 million from $741,000. For the first nine months, revenue was $1.410 million versus $468,000, and net loss was $7.285 million versus net income of $339,000.
Cash and equivalents were $137,000 as of September 30, 2026, while operating activities used $4.839 million during the nine months. Management said cash was not adequate to fund operations through at least 12 months from issuance, raising substantial doubt about the company’s ability to continue as a going concern; it plans to raise working capital through equity or debt.
Under its 2026 agreement with Yorkville, the company may sell up to $25 million of common stock over 36 months, at its option and subject to conditions including an effective resale registration statement; Yorkville generally pays 97% of Market Price. Yorkville and affiliates may not exceed 4.99% beneficial ownership, and without stockholder approval, issuance is capped at 19.9% of common stock outstanding on July 1, 2026. A 1-for-10 reverse split took effect September 29, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month revenue increased 201% to $1.410 million.
Negative
- Major pointCash of $137,000 was insufficient to fund operations through at least 12 months.
- Major pointNine-month results shifted to a $7.285 million net loss from $339,000 net income.
Filing Explained
By September 30, the 10-Q documents 413,059 related-party shares and 135,387 SEPA shares issued; October subscriptions covered 174,884 shares.
This 10-Q reports that in the first nine months of 2026, OneMedNet issued 413,059 shares to two related-party investors for
Those issuances add to the common-share base and reduce existing holders’ percentage ownership absent offsetting changes; the 2024 Yorkville agreement expired in
After quarter-end, OneMedNet entered into October subscription agreements covering 174,884 shares and received approximately
As of
Key Figures
Key Terms
iRWD technical
real-world evidence medical
going concern financial
standby equity purchase agreement financial
embedded put option financial
anti-dilutive financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue and net loss did ONMD report for Q3 2026?
What are the terms of ONMD’s 2026 Yorkville equity agreement?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
FOR THE TRANSITION PERIOD FROM TO
Commission
File Number
(Exact name of Registrant as specified in its Charter)
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate
by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
☐ No
As
of November 16, 2026, there were
Table of Contents
| Page | |||
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS | ii | ||
| PART I. | FINANCIAL INFORMATION | ||
| Item 1. | Condensed Consolidated Financial Statements | 1 | |
| Unaudited Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 | 1 | ||
| Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 | 2 | ||
| Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2026 and 2025 | 3 | ||
| Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 | 5 | ||
| Notes to Unaudited Condensed Consolidated Financial Statements | 6 | ||
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 19 | |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 27 | |
| Item 4. | Controls and Procedures | 27 | |
| PART II. | OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 28 | |
| Item 1A. | Risk Factors | 28 | |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 29 | |
| Item 3. | Defaults Upon Senior Securities | 29 | |
| Item 4. | Mine Safety Disclosures | 29 | |
| Item 5. | Other Information | 29 | |
| Item 6. | Exhibits | 29 | |
| Signature | 30 | ||
| i |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements that we make from time to time, including statements contained in this Quarterly Report on Form 10-Q (this “Report”) constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Report are forward-looking statements. The forward-looking statements in this Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. In some cases, you can identify these forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expects,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words. These forward-looking statements are based on our current expectations and projections regarding future events and trends that may affect our financial condition, results of operations, strategy, business objectives, and financial needs.
Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Forward-looking statements in this Report include, without limitation, statements reflecting management’s expectations regarding future financial performance and operating expenditures (including our ability to continue as a going concern, to raise additional capital and to succeed in our future operations), expected growth, profitability and business outlook, liquidity, operating expenses, and enhancement of our internal control structure.
Forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. These factors include, among other things, the unknown risks and uncertainties that we believe could cause actual results to differ from these forward looking statements as set forth under the heading, “Risk Factors” and elsewhere in this Report and other documents we file with the SEC. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to:
| ● | our projected financial position and estimated cash burn rate; | |
| ● | our estimates regarding expenses, future revenues and capital requirements; | |
| ● | our ability to continue as a going concern; | |
| ● | our ability to raise substantial additional capital in sufficient amounts or on acceptable terms to fund our operations and our business plan; | |
| ● | our ability to reverse the recent decline in our revenue and resume growing our revenue; | |
| ● | our ability to obtain and maintain intellectual property protection for our current products and services; |
| ii |
| ● | our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights; | |
| ● | the possibility that a third party may claim we have infringed, misappropriated or otherwise violated their intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against these claims; | |
| ● | our reliance on third-party suppliers; | |
| ● | the success of competing products or services that are or become available; | |
| ● | our ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel; | |
| ● | the potential for us to incur substantial costs resulting from lawsuits against us and the potential for these lawsuits to cause us to limit our commercialization of our products and services; and | |
| ● | changes in demand for our products and services as a result of geopolitical and/or macroeconomic conditions. |
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and in other documents we file with the Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Report may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Report to conform these statements to actual results or to changes in our expectations.
You should read this Report and the documents that we incorporate by reference in this Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements including those described in this Report and in the “Risk Factors” section of our Annual Report on Form 10-K and other documents we file with the Securities and Exchange Commission.
| iii |
PART I—FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
ONEMEDNET CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| September 30, 2026 | December 31, 2025 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Investment in crypto assets – Bitcoin | - | |||||||
| Accounts receivable, net | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and stockholders’ deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | $ | ||||||
| Deferred revenue | ||||||||
| Loans payable | ||||||||
| Advance from investor – related party | - | |||||||
| 2024 SEPA put option liability | - | |||||||
| Total current liabilities | ||||||||
| 2026 SEPA put option liability | - | |||||||
| Loans payable, net of current portion | ||||||||
| Warrant liabilities | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 14) | - | - | ||||||
| Stockholders’ deficit: | ||||||||
| Preferred Stock, par value $ |
- | - | ||||||
| Common Stock, par value $ |
||||||||
| Additional paid-in capital | ||||||||
| Treasury stock, at cost, |
( |
) | ( |
) | ||||
| Accumulated deficit | ( |
) | ( |
) | ||||
| Total stockholders’ deficit | ( |
) | ( |
) | ||||
| Total liabilities and stockholders’ deficit | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 1 |
ONEMEDNET CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
(Unaudited)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | ||||||||||||||||
| Subscription revenue | $ | - | $ | - | $ | - | $ | |||||||||
| Data delivery revenue | ||||||||||||||||
| Total revenue | ||||||||||||||||
| Cost of revenue | ||||||||||||||||
| Gross margin | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Sales and marketing | ||||||||||||||||
| Research and development | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other expense (income), net | ||||||||||||||||
| Interest expense | ||||||||||||||||
| Change in fair value of warrants | ( | ) | ( | ) | ||||||||||||
| Change in fair value of convertible notes | - | - | - | ( | ) | |||||||||||
| Change in fair value of crypto assets – Bitcoin | - | ( | ) | ( | ) | |||||||||||
| Realized loss (gain) on sale of crypto assets – Bitcoin | - | ( | ) | ( | ) | |||||||||||
| Change in fair value of 2024 SEPA derivative liabilities | - | ( | ) | ( | ) | |||||||||||
| Change in fair value of 2026 SEPA derivative liabilities | - | - | ||||||||||||||
| Gain on troubled debt restructurings | - | ( | ) | - | ( | ) | ||||||||||
| Loss on extinguishment of debt | - | - | ||||||||||||||
| Other expense (income) | ( | ) | ( | ) | ||||||||||||
| Total other expense (income), net | ( | ) | ( | ) | ||||||||||||
| Net (loss) income | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||
| Net (loss) income per share attributable to common shares – basic | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||
| Weighted average shares of common stock outstanding – basic | ||||||||||||||||
| Net (loss) income per share attributable to common shares – diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||
| Weighted average shares of common stock outstanding – diluted | ||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 2 |
ONEMEDNET CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN
STOCKHOLDERS’ DEFICIT
(In thousands, except share data)
(Unaudited)
Three and Nine Months Ended September 30, 2026
| Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||||||||
| Additional | Total | |||||||||||||||||||||||||||
| Common Stock | Treasury Stock | Paid-in | Accumulated | Stockholders’ | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||||||||
| Balances as of December 31, 2025 | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| Issuance of common stock in connection with 2024 SEPA | - | - | - | - | ||||||||||||||||||||||||
| Issuance of common stock in connection with subscription agreement with related party | - | - | - | - | ||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | - | |||||||||||||||||||||||
| Net loss | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||
| Balances as of March 31, 2026 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| Issuance of common stock in connection with 2024 SEPA | - | - | - | - | ||||||||||||||||||||||||
| Issuance of common stock in connection with subscription agreements with related parties | - | - | - | - | ||||||||||||||||||||||||
| Conversion of officer accrued salary into shares of common stock | - | - | - | - | ||||||||||||||||||||||||
| Issuance of common stock in connection with exercise of pre-funded warrants | - | - | - | - | - | - | ||||||||||||||||||||||
| Issuance of common stock in connection with exercise of warrants | - | - | - | - | ||||||||||||||||||||||||
| Vesting of restricted stock units | - | - | - | - | - | - | ||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | - | |||||||||||||||||||||||
| Net loss | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||
| Balances as of June 30, 2026 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| Issuance of common stock in connection with subscription agreements with related parties | - | - | - | - | ||||||||||||||||||||||||
| Vesting of restricted stock units | - | - | - | - | - | - | ||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | - | |||||||||||||||||||||||
| Net loss | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||
| Balances as of September 30, 2026 | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| 3 |
Three and Nine Months Ended September 30, 2025
| Additional | Total | |||||||||||||||||||||||||||
| Common Stock | Treasury Stock | Paid-in | Accumulated | Stockholders’ | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||||||||
| Balances as of December 31, 2024 | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| Issuance of common stock in connection with September 2024 private placement | - | - | - | - | - | - | ||||||||||||||||||||||
| Issuance of common stock upon partial conversion of Yorkville Note | - | - | - | - | ||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | - | |||||||||||||||||||||||
| Net loss | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||
| Balances as of March 31, 2025 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| Issuance of common stock in connection with settlement of vendor payable | - | - | - | - | ||||||||||||||||||||||||
| Issuance of common stock upon partial conversion of Yorkville Note | - | - | - | - | ||||||||||||||||||||||||
| Issuance of common stock upon conversion of loans with related parties | - | - | - | - | ||||||||||||||||||||||||
| Issuance of common stock upon conversion of PIPE Notes | - | - | - | - | ||||||||||||||||||||||||
| Issuance of common stock upon conversion of loan extensions with related parties | - | - | - | - | ||||||||||||||||||||||||
| Issuance of common stock in connection with June 2025 private placement | - | - | - | - | ||||||||||||||||||||||||
| Issuance of common stock in connection with subscription agreements with related parties | - | - | - | - | ||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | - | |||||||||||||||||||||||
| Net income | - | - | - | - | - | |||||||||||||||||||||||
| Balances as of June 30, 2025 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| Balance | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| Issuance of common stock in connection with pre-funded warrant exercises | - | - | - | - | - | - | ||||||||||||||||||||||
| Issuance of common stock in connection with subscription agreement with related party | - | - | - | - | ||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | - | |||||||||||||||||||||||
| Net loss | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||
| Net income (loss) | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||
| Balances as of September 30, 2025 | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| Balance | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 4 |
ONEMEDNET CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
| 2026 | 2025 | |||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net (loss) income | $ | ( | ) | $ | ||||
| Adjustments to reconcile net (loss) income to net cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Stock-based compensation expense | ||||||||
| Change in fair value of warrants | ( | ) | ||||||
| Change in fair value of convertible notes | - | ( | ) | |||||
| Change in fair value of crypto assets – Bitcoin | ( | ) | ||||||
| Change in fair value of 2024 SEPA derivative liabilities | ( | ) | ( | ) | ||||
| Change in fair value of 2026 SEPA derivative liabilities | - | |||||||
| Realized loss (gain) on sale of crypto assets – Bitcoin | ( | ) | ||||||
| Gain on troubled debt restructurings | - | ( | ) | |||||
| Loss on extinguishment of debt | - | |||||||
| Non-cash interest | - | |||||||
| Change in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Prepaid expenses and other current assets | ||||||||
| Accounts payable and accrued expenses | ||||||||
| Deferred revenue | ||||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | ( | ) | ( | ) | ||||
| Purchases of crypto assets – Bitcoin | - | ( | ) | |||||
| Sales of crypto assets – Bitcoin | ||||||||
| Net cash provided by investing activities | ||||||||
| Cash flows from financing activities: | ||||||||
| Proceeds from 2024 SEPA | - | |||||||
| Proceeds from subscription agreements with related parties | ||||||||
| Proceeds from investor advance – related party | - | |||||||
| Proceeds from exercise of warrants | - | |||||||
| Proceeds from private placement | - | |||||||
| Repayment of Yorkville Note | - | ( | ) | |||||
| Repayment of deferred underwriter fees payable | - | ( | ) | |||||
| Repayment of loans payable | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | ||||||||
| Net decrease in cash and cash equivalents | ( | ) | ( | ) | ||||
| Cash and cash equivalents at beginning of period | ||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Cash paid for taxes | $ | $ | - | |||||
| Supplemental disclosures of non-cash investing and financing activities: | ||||||||
| Conversion of officer accrued salary into shares of common stock | $ | $ | - | |||||
| Issuance of common stock in connection with settlement of vendor payable | $ | - | $ | |||||
| Issuance of common stock upon conversion of convertible notes | $ | - | $ | |||||
| Issuance of common stock upon conversion of loans with related parties | $ | - | $ | |||||
| Issuance of common stock upon conversion of loan extensions with related parties | $ | - | $ | |||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 5 |
ONEMEDNET CORPORATION
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Description of Business
Organization and Description of Business
OneMedNet Corporation (the “Company”) is a healthcare technology company focused on the acquisition, curation, de-identification and commercialization of real-world clinical data. Through its proprietary iRWD™ platform and network of healthcare providers, the Company provides pharmaceutical companies, medical device manufacturers, contract research organizations, academic institutions and artificial intelligence developers with access to longitudinal, multimodal clinical datasets for use in research, product development, regulatory submissions and real-world evidence generation.
The Company’s platform identifies, de-identifies and curates clinical data obtained from healthcare providers, including electronic health records, clinical notes, medical imaging, laboratory results and other clinical information. The Company combines its technology, healthcare provider network and clinical expertise to develop fit-for-purpose datasets based on customer-specific requirements.
The Company was incorporated in Delaware on November 20, 2015 and is headquartered in Eden Prairie, Minnesota. The Company has one wholly owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated under the Business Corporations Act (British Columbia).
On November 7, 2023, Data Knights Merger Sub, Inc., a wholly owned subsidiary of Data Knights Acquisition Corp., merged with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), with OneMedNet Solutions Corporation surviving as a wholly owned subsidiary. Following the consummation of the transaction, Data Knights Acquisition Corp. was renamed OneMedNet Corporation.
Basis of Presentation and Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain notes or other financial information normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the Company’s results for the interim periods presented. The results from operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the year ending December 31, 2026, or for any future annual or interim period.
The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes for the year ended December 31, 2025 in the Company’s Annual Report on Form 10-K, filed with the SEC on March 30, 2026 (the “Form 10-K”).
The interim unaudited condensed consolidated financial statements include the consolidated accounts of the Company’s wholly owned subsidiary, OneMedNet Technologies (Canada) Inc. All significant intercompany transactions have been eliminated in consolidation.
Reverse Stock Split
At the Company’s 2026 annual meeting of stockholders held on September 18, 2026, the Company’s stockholders approved a proposal to effect a reverse stock split of the Company’s common stock by a ratio ranging from any whole number between 1-for-5 and 1-for-20, as determined by the Board of Directors in its discretion.
On
September 29, 2026, the Company effected a
All information presented herein, unless otherwise indicated herein, reflects the Reverse Stock Split of the Company’s outstanding shares of common stock, and unless otherwise indicated, all such amounts and corresponding conversion price or exercise price data set forth herein have been adjusted to give effect to such Reverse Stock Split.
Liquidity and Going Concern
The
Company has incurred recurring net losses since its inception, including $
| 6 |
To continue and expand its operations, the Company will be required to, and management plans to, raise additional working capital through equity or debt offerings and ultimately hopes to attain profitable operations to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the condensed consolidated financial statements. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to raise capital and to achieve positive cash flow from operations.
Risks and Uncertainties
The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations, dependence on key personnel, and protection of proprietary technology.
In addition, the Company has previously invested in Bitcoin, which is a crypto asset. Crypto assets are loosely regulated and there is no central marketplace for currency exchange. Supply is determined by a computer code, not by a central bank, and prices have been extremely volatile. Certain crypto asset exchanges have been closed due to fraud, failure or security breaches. Any of the Company’s crypto assets that reside on an exchange that shuts down may be lost. Several factors may affect the price of crypto assets, including, but not limited to: supply and demand, investors’ expectations with respect to the rate of inflation, interest rates, currency exchange rates or future regulatory measures (if any) that restrict the trading of crypto assets, and the use of crypto assets as a form of payment. There is no assurance that crypto assets will maintain their long-term value in terms of purchasing power in the future, or that acceptance of crypto asset payments by mainstream retail merchants and commercial businesses will continue to grow.
As crypto assets have grown in popularity and market size, various countries and jurisdictions have begun to develop regulations governing the crypto asset industry. To the extent future regulatory actions or policies limit the ability to exchange crypto assets or utilize them for payments, the demand for crypto assets could be reduced. Furthermore, regulatory actions may limit the ability of end-users to convert crypto assets into fiat currency (e.g., U.S. dollars) or use crypto assets to pay for goods and services. Such regulatory actions or policies could result in a reduction of demand, and in turn, a decline in the underlying crypto asset unit prices.
The effect of any future regulatory change on crypto assets in general is impossible to predict, but such change could be substantial and adverse to the Company and the value of the Company’s investments in crypto assets.
Crypto assets are not insured or protected under the Federal Deposit Insurance Corporation (“FDIC”) or the Securities Investor Protection Corporation (“SIPC”). Accordingly, with respect to its historical Bitcoin investment, the Company did not enjoy the protections of other assets covered by the FDIC or SIPC. As of September 30, 2026, the Company no longer held any Bitcoin or other crypto assets.
2. Summary of Significant Accounting Policies
Except as described below, the accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Form 10-K, and the accounting policies followed by the Company for interim financial reporting are consistent with the accounting policies therein.
| 7 |
Reclassification
Certain prior period amounts have been reclassified to conform to the current year presentation. These reclassifications had no impact on the Company’s net loss, net cash flows, or stockholders’ deficit.
Accounting Pronouncements Not Yet Adopted
In November 2024, the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the consolidated financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03 on the presentation of its condensed consolidated financial statements and footnotes.
The Company has reviewed other recently issued accounting pronouncements and concluded that either they are not applicable to the business or no material effect is expected upon future adoption.
3. Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. The Company considers its chief executive officer to be the Company’s CODM. The CODM manages its operations and allocates resources based on the Company’s consolidated results and therefore operates as one segment.
The Company’s operations consist of its real-world data (“RWD”) platform, which enables life sciences and healthcare customers to access curated clinical and imaging datasets. The Company decommissioned its legacy BEAM platform in May 2025 as part of its strategic transition to a unified real-world data platform. Revenue associated with the BEAM platform was generated through the date of decommissioning and will not continue in future periods.
The Company’s method for measuring segment profitability is operating loss, which the CODM uses to assess performance and make decisions for resource allocation, consistent with the measurement principles for operating loss as reported on the Company’s condensed consolidated statements of operations. The CODM uses consolidated operating loss to set budgets, evaluate margins, review actual results, and to make decisions whether to engage in capital management transactions.
The significant expenses regularly reviewed by the CODM are consistent with those reported on the Company’s condensed consolidated statements of operations, and expenses are not regularly reviewed on a more disaggregated basis for purposes of assessing segment performance and deciding how to allocate resources.
The Company’s disaggregation of revenue by major product offering is consistent with its presentation on the Company’s condensed consolidated statements of operations. See Note 4 for revenue by geographic location.
| 8 |
4. Revenue
The Company’s disaggregation of revenue by major product offering is consistent with its presentation on the condensed consolidated statements of operations. Data delivery revenue is recognized at a point in time. Subscription revenue, which ceased following the decommissioning of the BEAM platform in May 2025, was recognized over time. The following table presents revenue by geographic region, based on the location of the customer (in thousands):
Schedule of Revenue by Geographic Region
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Americas | $ | $ | $ | $ | ||||||||||||
| Rest of World | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
Contract Balances
Accounts receivable, net includes unbilled receivables
of $
Deferred revenue consists of amounts invoiced or received
before data is delivered to and accepted by the customer and is recognized as revenue upon the customer’s acceptance of the data.
The increase in deferred revenue from December 31, 2025 to September 30, 2026 was primarily due to advance billings under iRWD contracts
for which data had not been delivered as of September 30, 2026. The beginning deferred revenue balances as of December 31, 2025 and December
31, 2024 were $
Remaining Performance Obligations
The Company’s remaining performance obligations consist of the delivery of contracted data units under iRWD contracts, which are recognized as revenue upon the customer’s acceptance of the data. The Company has elected the practical expedient in ASC 606-10-50-14 not to disclose the value of remaining performance obligations for contracts with an original expected duration of one year or less. For the remaining contracts, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied and expected to be recognized beyond 12 months is not material.
Customer Concentration
For the three and nine months ended September 30, 2026,
three customers each accounted for 10% or more of total revenue, together representing
For the three and nine months
ended September 30, 2025, five and two customers, respectively, each accounted for 10% or more of total revenue, together representing
| 9 |
5. Crypto Assets Held
The Company’s crypto assets are comprised solely of Bitcoin. In accordance with ASC Topic 820, Fair Value Measurement, the Company measures the fair value of its Bitcoin based on the quoted end-of-day price on the measurement date for a single Bitcoin on an active trading platform, River.com. Management has determined that River.com, an active exchange market, represents a principal market for Bitcoin and the end-of-day quoted price is both readily available and representative of fair value (Level 1 inputs). The following table sets forth the units held, cost basis, and fair value of its investments in crypto assets, as shown on the condensed consolidated balance sheets as of December 31, 2025 (in thousands):
Schedule of Crypto Assets Held
| December 31, 2025 | ||||||||||||
| Units | Cost Basis | Fair Value | ||||||||||
| Crypto assets held: | ||||||||||||
| Bitcoin | $ | $ | ||||||||||
| Total | $ | $ | ||||||||||
There were no crypto assets held by the Company as of September 30, 2026.
The following table presents a reconciliation of the fair values of the Company’s investments in crypto assets for the nine months ended September 30, 2026 (in thousands):
Schedule of Crypto Assets Reconciliation of Fair Values
| Bitcoin | ||||
| Balance, December 31, 2025 | $ | |||
| Dispositions | ( | ) | ||
| Unrealized gain, net | ||||
| Balance, September 30, 2026 | $ | - | ||
For
the nine months ended September 30, 2026, the Company had Bitcoin dispositions of $
6. Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses consisted of the following (in thousands):
Schedule of Accounts Payable and Accrued Expenses
| September 30, 2026 | December 31, 2025 | |||||||
| As of | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Professional fees | $ | $ | ||||||
| Software and technology | ||||||||
| Payroll liabilities | ||||||||
| Data provider costs | ||||||||
| Other | ||||||||
| Total | $ | $ | ||||||
| 10 |
In
April 2026, the Company issued
7. Debt
The following table summarizes outstanding debt for the periods indicated (in thousands):
Schedule of Outstanding Debt
| September 30, 2026 | December 31, 2025 | |||||||
| As of | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Loans payable | ||||||||
| Stock repurchase loan | $ | $ | ||||||
| Insurance premium loan | - | |||||||
| Extension loans | ||||||||
| Loans payable | ||||||||
| Long-term loans payable | ||||||||
| Extension loans | - | |||||||
| Stock repurchase loan | ||||||||
| Long- term loans payable | ||||||||
| Total | $ | $ | ||||||
8. Stockholders’ Deficit
2024 SEPA Draws
As
further described in the Form 10-K, the Company entered into a Standby Equity Purchase Agreement (“2024 SEPA”) with YA II
PN, LTD, a Cayman Islands exempt limited company (“Yorkville”), on June 17, 2024. Under the 2024 SEPA, the Company has the
right to sell to Yorkville up to $
The
commitment period under the 2024 SEPA expired in June 2026 and, therefore, the derivative liability was $
During
the nine months ended September 30, 2026, the Company delivered four advance notices for the sale of
The
estimated issuance date fair value and remeasurement adjustments for the embedded put and forward options are presented within other
expense (income), net under the caption change in fair value of 2024 SEPA derivative liabilities in the accompanying
condensed consolidated statements of operations. The embedded put option resulted in a fair value gain of $
| 11 |
2026 SEPA
On
July 1, 2026, the Company entered into a separate standby equity purchase agreement (the “2026 SEPA”) with Yorkville. Under
the 2026 SEPA, the Company has the right, but not the obligation, to sell to Yorkville up to $
Upon
satisfaction of the conditions set forth in the 2026 SEPA, including the effectiveness of a resale registration statement covering
the applicable shares, the Company may direct Yorkville to purchase a specified number of shares of Common Stock by delivering
written notice (each, an “Advance”).
Yorkville
will generally purchase shares pursuant to an Advance at a price per share equal to
The
2026 SEPA will automatically terminate on the earlier of (i) the 36-month anniversary of the agreement or (ii) the date on which Yorkville
has made payments for shares of Common Stock equal to the $
The 2026 SEPA was accounted for as a liability under ASC 815 as it includes an embedded put option and an embedded forward option. The put option is recognized at inception and the forward option is recognized upon issuance of notice for the sale of the Company’s Common Stock.
The
fair value of the derivative liability related to the embedded put option was estimated at $
Subscription Agreements – Related Parties
Between
February and September 2026, the Company entered into subscription agreements with two related party investors pursuant to which the
Company agreed to issue and sell an aggregate of
In
October 2026, the Company issued
ARC Forward Contract
As
of September 30, 2026 and December 31, 2025, the Company had an outstanding forward contract to issue
9. Net (Loss) Income per Share
Basic and diluted net (loss) income per share was calculated as follows:
Schedule of Basic and Diluted Net Income (Loss) per Share
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Numerator: | ||||||||||||||||
| Net (loss) income | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||
| Less: undistributed earnings attributable to participating warrant holders | - | - | - | $ | ( | ) | ||||||||||
| Net (loss) income attributable to common shareholders – basic | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||
| Reallocation of undistributed earnings attributable to participating warrant holders | - | $ | - | - | ||||||||||||
| Net (loss) income attributable to common shareholders – diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||
| Denominator: | ||||||||||||||||
| Weighted average shares of common stock outstanding – basic | ||||||||||||||||
| Net (loss) income per share attributable to common shares – basic | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||
| Effect of dilutive securities | ||||||||||||||||
| Restricted stock units | - | - | - | |||||||||||||
| Warrants | - | - | - | |||||||||||||
| Loan extensions | - | - | - | |||||||||||||
| Dilutive potential common shares | - | - | - | |||||||||||||
| Weighted average shares of common stock outstanding – diluted | ||||||||||||||||
| Net (loss) income per share attributable to common shares – diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||
| 12 |
For the three and nine months ended September 30, 2026, and three months ended September 30, 2025, during which the Company recorded a net loss, all potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered “anti-dilutive.” For these periods, the weighted average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share of common stock is the same.
For the nine months ended September 30, 2025, the Company reported net income. For this period, net income is allocated to the participating warrants and the Common Stock based on their participation rights. Under the two-class method, basic net income per share is computed by dividing net income attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. In addition, the dilutive effect of restricted stock units and warrants were calculated using the treasury stock method, whereby all such awards were assumed to be exercised at the beginning of the period. The hypothetical proceeds from such exercises, including the average unrecognized stock compensation expense for restricted stock units, were assumed to be used to purchase outstanding Common Stock at the average price during the period. The net share impact of dilutive securities was added to the weighted average basic common shares outstanding to calculate weighted average diluted shares outstanding.
The Company excluded the following potential shares of Common Stock, presented based on amounts outstanding at each period end, from the computation of diluted net (loss) income per share for the periods indicated because including them would have had an anti-dilutive effect:
Schedule of Antidilutive Earnings Per Share
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Restricted stock units | ||||||||||||||||
| Warrants for Common Stock | ||||||||||||||||
| Extension loans | - | - | - | |||||||||||||
| Total common stock equivalents | ||||||||||||||||
10. Stock-Based Compensation
The Company recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations for the periods presented (in thousands):
Schedule of Stock-Based Compensation
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three
Months Ended September 30, |
Nine
Months Ended September 30, |
|||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Cost of revenue | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Sales and marketing | ||||||||||||||||
| Research and development | ||||||||||||||||
| Total stock-based compensation expense | $ | $ | $ | $ | ||||||||||||
11. Stock Warrants
The Company has the following warrants outstanding for the periods presented:
Schedule of Warrants Outstanding
| September 30, 2026 | December 31, 2025 | |||||||
| As of | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Liability Classified Warrants | ||||||||
| Business Combination Warrants | ||||||||
| PIPE Warrants | ||||||||
| Subtotal | ||||||||
| Equity Classified Warrants | ||||||||
| Public Warrants | ||||||||
| Private Placement Warrants | ||||||||
| Subtotal | ||||||||
| Grand Total | ||||||||
| Warrants outstanding | ||||||||
| 13 |
On
June 30, 2026, the Company issued
12. Fair Value Measurements
The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, inclusive of related party (in thousands):
Schedule of Assets and Liabilities Measured at Fair Value
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| September 30, 2026 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Assets: | ||||||||||||||||
| Money market funds | $ | $ | - | $ | - | $ | ||||||||||
| Total assets, at fair value | $ | $ | - | $ | - | $ | ||||||||||
| Liabilities: | ||||||||||||||||
| Business Combination Warrants | $ | - | $ | - | $ | $ | ||||||||||
| PIPE Warrants | - | - | ||||||||||||||
| 2026 SEPA put option liability | - | - | ||||||||||||||
| Total liabilities, at fair value | $ | - | $ | - | $ | $ | ||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| December 31, 2025 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Assets: | ||||||||||||||||
| Money market funds | $ | $ | - | $ | - | $ | ||||||||||
| Bitcoin | - | - | ||||||||||||||
| Total assets, at fair value | $ | $ | - | $ | - | $ | ||||||||||
| Liabilities: | ||||||||||||||||
| Business Combination Warrants | $ | - | $ | - | $ | $ | ||||||||||
| PIPE Warrants | - | - | ||||||||||||||
| 2024 SEPA put option liability | - | - | ||||||||||||||
| Total liabilities, at fair value | $ | - | $ | - | $ | $ | ||||||||||
Business Combination Warrants and PIPE Warrants
The following table presents the changes in the Business Combination Warrants and PIPE Warrants measured at fair value during the three and nine months ended September 30, 2026 (in thousands):
Schedule of Warrants and Notes Measured at Fair Value
Business Combination Warrants | PIPE Warrants | |||||||
| Balance, December 31, 2025 | $ | $ | ||||||
| Changes in fair value | ( | ) | ( | ) | ||||
| Balance, March 31, 2026 | $ | $ | ||||||
| Changes in fair value | ( | ) | ( | ) | ||||
| Conversions to Common Stock | ||||||||
| Balance, June 30, 2026 | $ | $ | ||||||
| Changes in fair value | ( | ) | ( | ) | ||||
| Balance, September 30, 2026 | $ | $ | ||||||
| 14 |
The Company remeasured the fair value of the Business Combination Warrants and PIPE Warrants at September 30, 2026 using the Black-Scholes option-pricing model with the following assumptions:
Schedule of Fair Value Assumptions and Valuation
| Warrants | Warrants | |||||||
| As of September 30, 2026 | ||||||||
| PIPE | Business Combination | |||||||
| Warrants | Warrants | |||||||
| Stock price | $ | $ | ||||||
| Exercise price | $ | $ | ||||||
| Expected volatility | % | % | ||||||
| Weighted average risk-free rate | % | % | ||||||
| Expected dividend yield | % | % | ||||||
| Expected term (in years) | ||||||||
The Company remeasured the fair value of the Business Combination Warrants and PIPE Warrants at December 31, 2025 using the Black-Scholes option-pricing model with the following assumptions:
| Warrants | Warrants | |||||||
| As of December 31, 2025 | ||||||||
| PIPE | Business Combination | |||||||
| Warrants | Warrants | |||||||
| Stock price | $ | $ | ||||||
| Exercise price | $ | $ | ||||||
| Expected volatility | % | % | ||||||
| Weighted average risk-free rate | % | % | ||||||
| Expected dividend yield | % | % | ||||||
| Warrants measurement input | % | % | ||||||
| Expected term (in years) | ||||||||
2024 SEPA Derivative Liability
The 2024 SEPA expired in June 2026. The following table presents the changes in the 2024 SEPA derivative liabilities measured at fair value during the nine months ended September 30, 2026 (in thousands):
| 2024 SEPA Put Option | 2024 SEPA Forward Option | |||||||
| Balance, December 31, 2025 | $ | $ | - | |||||
| Changes in fair value | ( |
) | ( |
) | ||||
| Conversions to Common Stock | - | |||||||
| Balance, September 30, 2026 | $ | - | $ | - | ||||
| As of | ||||
| December 31, 2025 | ||||
| Term (in years) | ||||
| Starting stock price | $ | |||
| Expected volatility | % | |||
| Risk-free rate | % | |||
| Risk-free rate | % | |||
| 15 |
The 2024 SEPA forward option liability was deemed to have no value at December 31, 2025 as there were no outstanding notices for the sale of the Company’s Common Stock.
The commitment period under the 2024 SEPA expired in June 2026, therefore, the 2024 SEPA derivative liability balances were $0 at September 30, 2026.
2026 SEPA Derivative Liability
The following table presents the changes in the 2026 SEPA derivative liabilities measured at fair value during the nine months ended September 30, 2026 (in thousands):
Schedule of Warrants and Notes Measured at Fair Value
| 2026 SEPA Put Option | ||||
| Balance, December 31, 2025 | $ | - | ||
| Additions | ||||
| Changes in fair value | ( |
) | ||
| Balance, September 30, 2026 | $ | |||
The estimated fair value of the 2026 SEPA put option derivative liability was determined using a Monte Carlo simulation model in order to project the future path of the Company’s stock price over the commitment period with the following assumptions at September 30, 2026:
Schedule of Fair Value Assumptions and Valuation
| As of | ||||
| September 30, 2026 | ||||
| Term (in years) | ||||
| Starting stock price | $ | |||
| Expected volatility | % | |||
| Risk-free rate | % | |||
| Derivative liability | % | |||
| 16 |
The 2026 SEPA forward option liability was deemed to have no value at September 30, 2026 as there were no outstanding notices for the sale of the Company’s Common Stock.
13. Related Party Transactions
Conversion
of Officer Accrued Salary – As described in Note 6, the Company issued
Subscription
Agreements – As described in Note 8, the Company issued
In
September 2026, the Company also received a $
Accounting Services – The Company engages an accounting firm to provide accounting and bookkeeping services, which is majority owned by the Company’s Chief Financial Officer (“CFO”), who serves as an independent contractor to the Company.
For
the three and nine months ended September 30, 2026, the Company incurred expenses of $
As of September 30, 2026 and December 31, 2025, there were no amounts payable to the accounting firm.
Software Development Services – The Company engages a software development company to provide software development services, which is wholly owned by the Company’s Chief Technology Officer (“CTO”), who is an employee of the Company.
For
the three and nine months ended September 30, 2026, the Company incurred expenses of $
As
of September 30, 2026 and December 31, 2025, amounts payable to the CTO’s software development company were $
The Company believes that the terms of its arrangements with these vendors are consistent with those that would have been obtained from unaffiliated third parties.
14. Commitments and Contingencies
Lease Agreement
The
Company has a month-to-month lease for a suite at a cost of $
| 17 |
Litigation
From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recognized, if and when it is probable that a liability has been incurred and the amount can be reasonably estimated.
On November 6, 2025, ARC Group Limited and ARC Opportunity Fund Limited (together, “ARC”) filed a complaint against the Company and certain officers of the Company in the District Court of Minnesota, Fourth Judicial District (the “ARC complaint”). The ARC complaint alleges that the Company has breached certain contracts that the Company entered into with ARC before the closing of the Business Combination, including certain financial advisory contracts entered into by the Company at the direction of the sponsor of the Business Combination (the “sponsor”; the Company notes that the sponsor is an affiliate of ARC). Specifically, the ARC complaint asserts that the Company breached these contracts by issuing certain shares of Common Stock to ARC contemporaneously with the closing of the Business Combination and improperly cancelling those shares after the Business Combination as well as by failing to pay ARC certain cash amounts when due. The ARC complaint seeks an order of specific performance requiring the Company to reinstate the cancelled shares of Common Stock or, in the alternative, compensatory damages for such cancellation as well as payment of the other purported amounts due. The ARC complaint also asserts tort claims arising out of the Company’s actions and seeks compensatory damages (plus prejudgment interest) and punitive damages in connection with such claims but does not specify an amount of damages.
The
Company notes that no shares of Common Stock were actually issued to ARC prior to or contemporaneously with the closing of the Business
Combination and that, as of September 30, 2026 and as previously disclosed on the Form 10-K for the fiscal year ended December 31, 2025,
the Company has recorded a forward contract to issue
The Company was not subject to any other material legal proceedings during the nine months ended September 30, 2026.
15. Subsequent Events
The Company has evaluated subsequent events occurring through November 16, 2026, the date the condensed consolidated financial statements were issued, for events requiring recording or disclosure in the Company’s condensed consolidated financial statements.
In
October 2026, the Company entered into subscription agreements with two related party investors pursuant to which the Company agreed
to issue and sell an aggregate of
| 18 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis are intended to help you understand our business, financial condition, results of operations, liquidity, and capital resources. You should read this discussion in conjunction with the Company’s consolidated financial statements and related notes included elsewhere in this Report and in the Form 10-K.
In addition to historical financial analysis, this discussion and analysis contains forward-looking statements based upon current expectations that involve risks, uncertainties, and assumptions, as described under the heading “Cautionary Note Regarding Forward-Looking Statements.” Actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of various factors, risks and uncertainties, including those set forth under “Risk Factors” included elsewhere (or incorporated by reference) in this Report and in the Form 10-K. Unless the context otherwise requires, references in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” to “OneMedNet”, “we”, “us”, “our,” and “the Company” are intended to mean the business and operations of OneMedNet Corporation and its consolidated subsidiary following the completion of the business combination on November 7, 2023 involving OneMedNet Solutions Corporation (formerly named OneMedNet Corporation) (“Legacy ONMD”), with Legacy ONMD surviving as a wholly owned subsidiary of Data Knights Acquisition Corp. (“Data Knights”) (the “Business Combination”).
Company Overview
We are a healthcare technology company focused on the acquisition, curation, de-identification and commercialization of real-world clinical data. Through our proprietary iRWD™ platform and network of healthcare providers, we provide pharmaceutical companies, medical device manufacturers, contract research organizations, academic institutions and artificial intelligence developers with access to longitudinal, multimodal clinical datasets for use in research, product development, regulatory submissions and real-world evidence generation.
Our platform identifies, de-identifies and curates clinical data obtained from healthcare providers, including electronic health records, clinical notes, medical imaging, laboratory results and other clinical information. We combine our technology, healthcare provider network and clinical expertise to develop fit-for-purpose datasets based on customer-specific requirements.
Reverse Stock Split
At the Company’s 2026 annual meeting of stockholders held on September 18, 2026, the Company’s stockholders approved a proposal to effect a reverse stock split of the Company’s common stock by a ratio ranging from any whole number between 1-for-5 and 1-for-20, as determined by the Board of Directors in its discretion.
On September 29, 2026, the Company effected a 1-for-10 reverse stock split of the Company’s common stock, par value $0.0001 per share (“Common Stock”) (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 10 shares of the Company’s Common Stock issued and outstanding were automatically converted into one new share of Common Stock. Proportionate adjustments were also made to the number of shares available under the Company’s equity incentive plans and the exercise price and number of shares underlying outstanding restricted stock units, warrants, and other equity awards. The Reverse Stock Split did not decrease the number of authorized shares of Common Stock and preferred stock or otherwise affect the par value of the Common Stock. No fractional shares were issued in connection with the Reverse Stock Split and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share for stockholders of record who would be entitled to receive fractional shares pursuant to the Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Company effecting the Reverse Stock Split.
All information presented herein, unless otherwise indicated herein, reflects the Reverse Stock Split of the Company’s outstanding shares of common stock, and unless otherwise indicated, all such amounts and corresponding conversion price or exercise price data set forth herein have been adjusted to give effect to such Reverse Stock Split.
Nasdaq Compliance
On April 14, 2026, the Company received notice from The Nasdaq Stock Market (“Nasdaq”) indicating that the Company, based on the closing bid price of the shares of Common Stock for the last 30 consecutive business days, is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 12, 2026, to regain compliance with the Bid Price Rule. To regain compliance, the minimum bid price of the shares of Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-calendar day grace period.
On October 13, 2026, we received a letter from Nasdaq notifying us that we had regained compliance with the Bid Price Rule and accordingly, the matter is now closed.
Key Components of Consolidated Statements of Operations
Revenue
The Company generates revenue from its iRWD platform, which provides regulatory grade imaging and clinical data in the pharmaceutical, device manufacturing, contract research organizations, and AI markets. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered and accepted by the customer. The Company’s legacy BEAM platform was decommissioned in May 2025, and no revenue was generated from this platform thereafter.
| 19 |
The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. The transaction price for the products is the invoiced amount. Advance billings from contracts are deferred and recognized as revenue when earned. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable are recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.
Cost of Revenue
Our cost of revenue consists primarily of (i) software and hosting costs associated with operating our real-world data platform, (ii) data costs, which include amounts paid to data partners to acquire the clinical and imaging data we deliver to customers, and (iii) personnel costs for employees directly involved in curating and delivering data.
General and Administrative
General and administrative functions include finance, legal, operations, human resources, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, and depreciation expense.
Research and Development
Costs incurred in the research and development of our products are expensed as incurred. Research and development costs include personnel, contracted services, materials, and indirect costs involved in the design and development of new products and services, as well as hosting expense.
Sales and Marketing
Our sales and marketing costs consist of labor and tradeshow costs.
Other (Income) Expenses, Net
Interest Expense
Interest expense consists of interest incurred on our outstanding debt facilities, including loans with related parties, deferred underwriter fees and insurance premiums paid in exchange for a note payable.
Change in Fair Value of Warrants
We have outstanding warrants that were issued at the closing of the Business Combination, which are accounted for as liabilities at fair value. These warrants are subsequently re-measured at fair value on our consolidated balance sheets at the end of each reporting period and at settlement, as applicable, and changes in fair value are recognized in the consolidated statements of operations.
Change in Fair Value of Convertible Notes
We have elected the fair value option of accounting for the PIPE Notes (as defined in the Form 10-K) issued in the Business Combination and the Yorkville Note (as defined in the Form 10-K) issued with the 2024 SEPA. These instruments contained embedded derivatives that would require bifurcation and separate accounting; therefore, we made the election to measure the entire contingently convertible debt instruments, including accrued interest, at fair value. These instruments are subsequently re-measured at fair value on our consolidated balance sheets at the end of each reporting period and at settlement, as applicable, and changes in fair value are recognized in the consolidated statements of operations. The PIPE Notes and Yorkville Note were both settled in 2025 and were no longer outstanding as of December 31, 2025.
| 20 |
Change in Fair Value of Crypto Assets – Bitcoin
We previously adopted a Bitcoin strategy on the balance sheets as a forward-looking approach to corporate treasury management that incorporates digital currencies. Our Bitcoin holdings were held at fair value on the consolidated balance sheets and are re-measured at the end of each reporting period based on the quoted end-of-day price provided by a reputable and liquid exchange. As of September 30, 2026, we no longer hold Bitcoin or any other crypto assets.
Realized Loss (Gain) on Sale of Crypto Assets – Bitcoin
As part of our Bitcoin strategy, we routinely sell quantities held as part of our corporate treasury strategy to fund operations as needed. We recognize a realized gain upon sale when the price of Bitcoin is higher than its initial purchase price.
Change in Fair Value of SEPA Derivative Liabilities
We entered into the 2024 SEPA and 2026 SEPA, which provide us with the right, but not the obligation, to require Yorkville to purchase shares of our Common Stock during the respective commitment periods, subject to certain limitations. We recognize a put option liability upon execution of each SEPA and a forward option liability upon delivery of a notice to sell shares of our Common Stock. These derivative liabilities are subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in our consolidated statements of operations.
Results of Operations
Comparison of the Three Months Ended September 30, 2026 and 2025
The following table sets forth our condensed consolidated statements of operations data for the periods presented (in thousands):
| Three Months Ended September 30, | Change | |||||||||||||||
| 2026 | 2025 | $ | % | |||||||||||||
| Revenue | ||||||||||||||||
| Data delivery revenue | 1,023 | 177 | 846 | 478 | % | |||||||||||
| Total revenue | 1,023 | 177 | 846 | 478 | % | |||||||||||
| Cost of revenue | 1,386 | 399 | 987 | 247 | % | |||||||||||
| Gross margin | (363 | ) | (222 | ) | (141 | ) | 64 | % | ||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | 1,185 | 1,386 | (201 | ) | -15 | % | ||||||||||
| Sales and marketing | 262 | 304 | (42 | ) | -14 | % | ||||||||||
| Research and development | 424 | 323 | 101 | 31 | % | |||||||||||
| Total operating expenses | 1,871 | 2,013 | (142 | ) | -7 | % | ||||||||||
| Loss from operations | (2,234 | ) | (2,235 | ) | 1 | -0 | % | |||||||||
| Other (income) expense, net | ||||||||||||||||
| Interest expense | 8 | 6 | 2 | 33 | % | |||||||||||
| Change in fair value of warrants | (19 | ) | 20 | (39 | ) | -195 | % | |||||||||
| Change in fair value of crypto assets – Bitcoin | - | (55 | ) | 55 | -100 | % | ||||||||||
| Realized gain on sale of crypto assets – Bitcoin | - | (54 | ) | 54 | -100 | % | ||||||||||
| Change in fair value of 2024 SEPA derivative liabilities | - | 402 | (402 | ) | -100 | % | ||||||||||
| Change in fair value of 2026 SEPA derivative liabilities | 436 | - | 436 | 100 | % | |||||||||||
| Gain on troubled debt restructurings | - | (1,862 | ) | 1,862 | -100 | % | ||||||||||
| Loss on extinguishment of debt | - | 41 | (41 | ) | -100 | % | ||||||||||
| Other expense, net | 1 | 8 | (7 | ) | -88 | % | ||||||||||
| Total other expense (income), net | 426 | (1,494 | ) | 1,920 | -129 | % | ||||||||||
| Net (loss) income | $ | (2,660 | ) | $ | (741 | ) | $ | (1,919 | ) | -259 | % | |||||
| 21 |
Revenue
Total revenue increased by $0.8 million, or 478%, during the three months ended September 30, 2026, compared to the three months ended September 30, 2025. The increase was attributable to a $0.8 million increase in data delivery revenue as the Company continued its transition to a unified RWD platform, driving increased customer adoption and higher data delivery volumes.
Cost of Revenue
Cost of revenue was $1.4 million for the three months ended September 30, 2026, compared to $0.4 million for the three months ended September 30, 2025, an increase of $1.0 million, or 247%. The increase was primarily driven by a $0.5 million increase in software and hosting costs associated with operating and scaling the Company’s AI-enabled real-world data platform, a $0.4 million increase in iRWD costs to support higher data delivery revenue through the iRWD platform, and a $0.1 million increase in personnel costs due to headcount growth.
General and Administrative
General and administrative expenses were $1.2 million for the three months ended September 30, 2026, compared to $1.4 million for the three months ended September 30, 2025, a decrease of $0.2 million, or 15%. The decrease was primarily attributable to a $0.4 million decrease in professional fees, largely due to lower consulting and legal costs, which is partially offset by a $0.2 million increase in share-based compensation expense related to equity awards granted during the second half of 2025 and 2026,
Sales and Marketing
Sales and marketing expenses for the three months ended September 30, 2026, were generally consistent with sales and marketing expenses for the three months ended September 30, 2025.
Research and Development
Research and development expenses were $0.4 million for the three months ended September 30, 2026, compared to $0.3 million for the three months ended September 30, 2025, an increase of $0.1 million, or 31%. The increase was primarily attributable to a $0.1 million increase in share-based compensation expense related to equity awards granted during the second half of 2025 and 2026.
Interest Expense
Interest expense for the three months ended September 30, 2026 was generally consistent with interest expense for the three months ended September 30, 2025.
| 22 |
Change in Fair Value of Warrants
The change in fair value of warrants is composed of the re-measurement adjustment for our liability-classified warrants that were issued in connection with the Business Combination. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock.
Change in Fair Value of Crypto Assets – Bitcoin
The change in fair value of crypto assets – Bitcoin during the three months ended September 30, 2025, reflected fluctuations in the price of Bitcoin. There was no corresponding change in fair value during the three months ended September 30, 2026, as we liquidated all of our Bitcoin holdings during the second quarter of 2026.
Realized Gain on Sale of Crypto Assets – Bitcoin
The realized gain on sale of crypto assets – Bitcoin during the three months ended September 30, 2025, reflected the difference between the carrying value of Bitcoin and its market price upon sale. There was no corresponding realized gain during the three months ended September 30, 2026, as we liquidated all of our Bitcoin holdings during the second quarter of 2026.
Change in Fair Value of SEPA Derivative Liabilities
The change in fair value of SEPA derivative liabilities is primarily driven by assumptions regarding the expected timing and volume of Common Stock sales to Yorkville and the Company’s projected stock price over the applicable commitment period. The change in fair value during the three months ended September 30, 2026, related to the 2026 SEPA, while the change in fair value during the three months ended September 30, 2025, related to the 2024 SEPA.
Gain on Troubled Debt Restructurings
Gain on troubled debt restructurings during the three months ended September 30, 2025 was primarily driven by restructured trade payables with two separate vendors which resulted in a gain of $1.9 million. During the three months ended September 30, 2026, we did not restructure any of our debt or trade payables.
Comparison of the Nine Months Ended September 30, 2026 and 2025
The following table sets forth our condensed consolidated statements of operations data for the periods presented (in thousands):
| Nine Months Ended September 30, | Change | |||||||||||||||
| 2026 | 2025 | $ | % | |||||||||||||
| Revenue | ||||||||||||||||
| Subscription revenue | $ | - | $ | 105 | $ | (105 | ) | -100 | % | |||||||
| Data delivery revenue | 1,410 | 363 | 1,047 | 288 | % | |||||||||||
| Total revenue | 1,410 | 468 | 942 | 201 | % | |||||||||||
| Cost of revenue | 2,928 | 1,136 | 1,792 | 158 | % | |||||||||||
| Gross margin | (1,518 | ) | (668 | ) | (850 | ) | 127 | % | ||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | 3,439 | 3,999 | (560 | ) | -14 | % | ||||||||||
| Sales and marketing | 1,031 | 846 | 185 | 22 | % | |||||||||||
| Research and development | 1,059 | 1,072 | (13 | ) | -1 | % | ||||||||||
| Total operating expenses | 5,529 | 5,917 | (388 | ) | -7 | % | ||||||||||
| Loss from operations | (7,047 | ) | (6,585 | ) | (462 | ) | 7 | % | ||||||||
| Other (income) expense, net | ||||||||||||||||
| Interest expense | 27 | 59 | (32 | ) | -54 | % | ||||||||||
| Change in fair value of warrants | (66 | ) | 23 | (89 | ) | -387 | % | |||||||||
| Change in fair value of convertible notes | - | (1,285 | ) | 1,285 | -100 | % | ||||||||||
| Change in fair value of crypto assets – Bitcoin | (147 | ) | 782 | (929 | ) | -119 | % | |||||||||
| Realized loss (gain) on sale of crypto assets – Bitcoin | 234 | (899 | ) | 1,133 | -126 | % | ||||||||||
| Change in fair value of 2024 SEPA derivative liabilities | (245 | ) | (32 | ) | (213 | ) | 666 | % | ||||||||
| Change in fair value of 2026 SEPA derivative liabilities | 436 | - | 436 | 100 | % | |||||||||||
| Gain on troubled debt restructurings | - | (5,569 | ) | 5,569 | -100 | % | ||||||||||
| Loss on extinguishment of debt | - | 41 | (41 | ) | -100 | % | ||||||||||
| Other (income) expense, net | (1 | ) | (44 | ) | 43 | -98 | % | |||||||||
| Total other (income) expense, net | 238 | (6,924 | ) | 7,162 | -103 | % | ||||||||||
| Net (loss) income | $ | (7,285 | ) | $ | 339 | $ | (7,624 | ) | -2249 | % | ||||||
| 23 |
Revenue
Total revenue increased by $0.9 million, or 201%, during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. The increase was primarily attributable to a $1.0 million increase in data delivery revenue as the Company continued its transition to a unified RWD platform, driving increased customer adoption and higher data delivery volumes. This growth was partially offset by a $0.1 million decrease in subscription revenue due to the decommissioning of the BEAM platform in May 2025.
Cost of Revenue
Cost of revenue was $2.9 million for the nine months ended September 30, 2026, compared to $1.1 million for the nine months ended September 30, 2025, an increase of $1.8 million, or 158%. The increase was primarily driven by a $1.1 million increase in software and hosting costs associated with operating and scaling the Company’s AI-enabled real-world data platform, a $0.5 million increase in iRWD costs to support higher data delivery revenue through the iRWD platform, and a $0.2 million increase in personnel costs due to headcount growth.
General and Administrative
General and administrative expenses were $3.4 million for the nine months ended September 30, 2026, compared to $4.0 million for the nine months ended September 30, 2025, representing a decrease of $0.6 million, or 14%. The decrease was primarily attributable to a $1.0 million reduction in professional fees, primarily due to lower legal, consulting, and other professional service costs, and a $0.1 million decrease in other general and administrative expenses. These decreases were partially offset by a $0.5 million increase in share-based compensation expense related to equity awards granted during 2025 and 2026 and a $0.1 million increase in salaries and related personnel costs resulting from headcount growth.
Sales and Marketing
Sales and marketing expenses were $1.0 million for the nine months ended September 30, 2026, compared to $0.8 million for the nine months ended September 30, 2025, representing an increase of $0.2 million, or 22%. The increase was primarily attributable to a $0.1 million increase in personnel costs due to headcount growth and a $0.1 million increase in consulting costs resulting from business development initiatives intended to support growth of the Company’s iRWD platform.
Research and Development
Research and development expenses for the nine months ended September 30, 2026, were generally consistent with research and development expenses for the nine months ended September 30, 2025.
| 24 |
Interest Expense
Interest expense for the nine months ended September 30, 2026 was generally consistent with interest expense for the nine months ended September 30, 2025.
Change in Fair Value of Warrants
The change in fair value of warrants is composed of the re-measurement adjustment for our liability-classified warrants that were issued in connection with the Business Combination. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock.
Change in Fair Value of Convertible Notes
The change in fair value of convertible notes is composed of the re-measurement adjustment for the PIPE Notes and Yorkville Note which are carried at fair value. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock. Both instruments were converted or repaid in the second quarter of 2025; therefore, no re-measurement adjustment was required for the nine months ended September 30, 2026.
Change in Fair Value of Crypto Assets – Bitcoin
The change in fair value of crypto assets – Bitcoin during the nine months ended September 30, 2026 and 2025 reflected fluctuations in the price of Bitcoin.
Realized Loss (Gain) on Sale of Crypto Assets – Bitcoin
The realized loss (gain) on sale of crypto assets – Bitcoin during the nine months ended September 30, 2026 and 2025 reflected the difference between the carrying value of Bitcoin and its market price upon sale.
Change in Fair Value of SEPA Derivative Liabilities
The change in fair value of SEPA derivative liabilities is primarily driven by assumptions regarding the expected timing and volume of Common Stock sales to Yorkville and the Company’s projected stock price over the applicable commitment period. For the nine months ended September 30, 2026, the change in fair value included amounts related to both the 2024 SEPA and the 2026 SEPA, whereas the change in fair value for the nine months ended September 30, 2025, related solely to the 2024 SEPA.
Gain on Troubled Debt Restructurings
Gain on troubled debt restructurings during the nine months ended September 30, 2025 was primarily driven by our settlement of deferred underwriter fees which resulted in a gain of $2.8 million. In addition, we restructured trade payables with five separate vendors leading to an additional gain of $2.8 million. During the nine months ended September 30, 2026, we did not restructure any of our debt or trade payables.
Liquidity and Capital Resources
As of September 30, 2026, our principal sources of liquidity were proceeds from related party investors and the 2024 SEPA.
The following table shows net cash and cash equivalents used in operating activities, net cash and cash equivalents used in investing activities, and net cash and cash equivalents provided by financing activities during the periods presented:
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net cash provided by (used in) | ||||||||
| Operating activities | $ | (4,839 | ) | $ | (5,455 | ) | ||
| Investing activities | 407 | 2,358 | ||||||
| Financing activities | 3,984 | 3,074 | ||||||
| 25 |
Operating Activities
Our net cash and cash equivalents used in operating activities consists of net loss adjusted for certain non-cash items, including depreciation and amortization, stock-based compensation expense, changes in fair value of liability classified financial instruments, as well as changes in operating assets and liabilities. The primary changes in working capital items, such as the changes in accounts receivable and deferred revenue, result from the difference in timing of payments from our customers related to contract performance obligation. This may result in an operating cash flow source or use for the period, depending on the timing of payments received as compared to the fulfillment of the performance obligation.
During the nine months ended September 30, 2026, we used $4.8 million of cash in operating activities, primarily resulting from our net loss of $7.3 million, offset by non-cash charges of $1.6 million and cash provided by changes in our operating assets and liabilities of $0.9 million.
During the nine months ended September 30, 2025, we used $5.5 million of cash in operating activities, primarily resulting from non-cash charges of $6.3 million, offset by our net income of $0.3 million and cash provided by changes in our operating assets and liabilities of $0.5 million.
Investing Activities
Our investing activities have consisted primarily of property and equipment purchases and Bitcoin purchases and sales.
During the nine months ended September 30, 2026, net cash provided by investing activities was $0.4 million, primarily consisting of proceeds from Bitcoin sales of $0.4 million.
During the nine months ended September 30, 2025, net cash provided by investing activities was $2.4 million, primarily consisting of proceeds from Bitcoin sales of $4.8 million offset by Bitcoin purchases of $2.4 million.
Financing Activities
During the nine months ended September 30, 2026, net cash provided by financing activities was $4.0 million, consisting of $3.4 million in net proceeds from related party investments and $1.0 million in net proceeds from the 2024 SEPA, partially offset by debt repayments of $0.4 million.
During the nine months ended September 30, 2025, net cash provided by financing activities was $3.1 million, consisting of $1.7 million in net proceeds from related party investments and $2.5 million in net proceeds from private placements, partially offset by aggregate repayments of $1.1 million of debt and deferred underwriter fees.
Contractual Obligations and Commitments and Going Concern Outlook
Currently, management does not believe that our cash and cash equivalents are sufficient to meet our foreseeable cash needs for at least the next 12 months. Our foreseeable cash needs, in addition to our recurring operating expenses, include our expected capital expenditures to support the expansion of our infrastructure and workforce, interest expense and minimum contractual obligations. Management intends to raise cash for operations through debt and equity offerings. As a result of the Company’s recurring loss from operations and the need for additional financing to fund its operating and capital requirements there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.
Our future capital requirements will depend on many factors, including our growth rate, the timing and extent of spending to support research and development efforts, the expansion of sales and marketing activities, the introduction of new and enhanced product and service offerings, and the cost of any future acquisitions of technology or businesses. In the event that additional financing is required from outside sources, we may be unable to raise the funds on acceptable terms, if at all.
| 26 |
The following table summarizes our material cash requirements as of September 30, 2026:
| Payments due in: | ||||||||||||
| Total | Less than 1 year | 1-3 years | ||||||||||
| Accounts payable & accrued expenses | $ | 4,504 | $ | 4,504 | $ | - | ||||||
| Loans payable | 563 | 464 | 99 | |||||||||
| $ | 5,067 | $ | 4,968 | $ | 99 | |||||||
Critical Accounting Policies and Estimates
Our management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements which have been prepared in accordance with GAAP. In preparing our financial statements, we make estimates, assumptions, and judgments that can have a significant impact on our reported revenue, results of operations, and net income or loss, as well as on the value of certain assets and liabilities on our balance sheet during and as of the reporting periods. These estimates, assumptions, and judgments are necessary because future events and their effects on our results of operations and the value of our assets cannot be determined with certainty and are made based on our historical experience and on other assumptions that we believe to be reasonable under the circumstances. These estimates may change as new events occur or additional information is obtained, and we may periodically be faced with uncertainties, the outcomes of which are not within our control and may not be known for a prolonged period of time. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates.
For a discussion of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Form 10-K, the notes to our audited financial statements appearing in the Form 10-K, and the notes to the financial statements appearing elsewhere in this Report. Except as described in this Report, there have been no material changes to these critical accounting policies and estimates through September 30, 2026 from those discussed in the Form 10-K.
Recently Issued and Adopted Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements included elsewhere in this Report.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), as of September 30, 2026. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were ineffective due to material weaknesses in our internal controls over financial reporting related to user access and segregation of duties, the lack of a formalized control environment and oversight of controls over financial reporting, and revenue recognition.
| 27 |
Material Weaknesses
Management is aware of material weaknesses in the Company’s internal control related to user access/segregation of duties, lack of a formalized control environment and oversight of controls over financial reporting and revenue recognition. Due to the limited transactional volume currently experienced, combined with our financial limitations, we do not currently have an expanded accounting department that would allow us to better segregate duties. Over time, as we continue to grow and add accounting staff, we expect to continue to enhance our internal control structure, including appropriate segregation of duties. Management has begun taking remediation steps to address the material weaknesses, including the hiring of a full-time controller in July 2025 and adding additional review procedures over our financial records. This remediation is an ongoing process and there can be no assurance that it will effectively address the material weaknesses.
Changes in Internal Control Over Financial Reporting
Except as described above, there were no other changes in our internal control over financial reporting during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
Item 1. Legal Proceedings.
For information regarding litigation, see Part I – Item 1. Condensed Consolidated Financial Statements, Note 14 - Commitments and Contingencies.
Item 1A. Risk Factors.
In addition to the other information set forth in this Report, you should carefully consider the factors discussed in the “Risk Factors” in the Form 10-K and our other public filings, which could materially affect our business, financial condition or future results. There have been no material changes from risk factors previously disclosed in “Risk Factors” in the Form 10-K and our other public filings.
| 28 |
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
The Company entered into a subscription agreement, dated July 30, 2026, with Dr. Thomas Kosasa, a director and related party of the Company, pursuant to which the Company issued 144,928 shares of Common Stock to Dr. Kosasa at a price of $6.90 per share. The Company received net proceeds of approximately $1,000,000 from the related party subscription agreement. These shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) under the Securities Act.
The Company entered into a subscription agreement, dated September 10, 2026, with Dr. Jeffrey Yu, a director, officer and related party of the Company, pursuant to which the Company issued 14,286 shares of Common Stock to Dr. Yu at a price of $6.30 per share. The Company received net proceeds of approximately $90,000 from the related party subscription agreement. These shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) under the Securities Act.
Except as set forth above, during the three months ended September 30, 2026, we did not have issuances of unregistered securities not previously included in a Current Report on Form 8-K.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
During
the three months ended September 30, 2026, no director or officer of the Company
Item 6. Exhibits.
The following documents are included as exhibits to this Report:
| Exhibit Number | Description | |
| 3.1 | Third Amended and Restated Certificate of Incorporation of OneMedNet Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K, filed with the SEC on November 13, 2023). | |
| 3.2 | Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of OneMedNet Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K, filed with the SEC on September 29, 2026). | |
| 3.3 | Amended and Restated Bylaws of OneMedNet Corporation (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on November 13, 2023). | |
| 10.1 | Standby Equity Purchase Agreement, dated as of July 1, 2026, by and between OneMedNet Corporation and YA II PN, Ltd. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 1, 2026). | |
| 10.2* | OneMedNet Corporation Amended and Restated 2022 Equity Incentive Plan. | |
| 31.1* | Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 31.2* | Certification of Chief Financial Officer (Principal Financial Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 32.1# | Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 32.2# | Certification of Chief Financial Officer (Principal Financial Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
* Filed herewith.
# The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Report and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.
| 29 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 16, 2026.
| OneMedNet Corporation | ||
| By: | /s/ Robert Golden | |
| Robert Golden | ||
| Chief Financial Officer | ||
| (Duly Authorized Officer and Principal Financial and Accounting Officer) | ||
| 30 |